$GILD Recent News Rival to Gilead's pricey Sov
Post# of 72709
Posted On: 06/18/2014 10:00:08 AM
$GILD Recent News
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. Today - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks 8:38 a.m. Today - benzinga.com
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog 5:20 p.m. June 17, 2014 - Zacks.com
Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog 5:00 p.m. June 17, 2014 - Zacks.com
AbbVie's Avenue for Gains 4:47 p.m. June 17, 2014 - Barrons.com
Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog 4:47 p.m. June 17, 2014 - Zacks.com
Glaxo's Promacta Holds Promise - Analyst Blog 4:45 p.m. June 17, 2014 - Zacks.com
Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog 4:35 p.m. June 17, 2014 - Zacks.com
Valeant Receives FDA's Clearance for Restylane - Analyst Blog 3:05 p.m. June 17, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) 1:57 p.m. June 17, 2014 - Seeking Alpha
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog 1:40 p.m. June 17, 2014 - Zacks.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Orexigen (OREX) in Focus: Stock Moves 7.5% Higher - Tale of the Tape 9:46 a.m. June 17, 2014 - Zacks.com
Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% - Tale of the Tape 9:39 a.m. June 17, 2014 - Zacks.com
Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape 8:51 a.m. June 17, 2014 - Zacks.com
Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape 8:44 a.m. June 17, 2014 - Zacks.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
Actelion's Selexipag Meets Primary Endpoint - Analyst Blog 6:15 p.m. June 16, 2014 - Zacks.com
Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog 6:10 p.m. June 16, 2014 - Zacks.com
OncoMed's OMP-18R5 On Clinical Hold, Shares Down - Analyst Blog 5:22 p.m. June 16, 2014 - Zacks.com
Agios Presents Data on AG-221 - Analyst Blog 5:21 p.m. June 16, 2014 - Zacks.com
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
Rival to Gilead's pricey Sovaldi expected to hit market later this year 7:28 a.m. Today - blogs.marketwatch.com
Tyson falls on Hillshire deal; Apple gains post-split 3:49 p.m. June 9, 2014 - Saumya Vaishampayan
Lobbyists for insurers, big pharma trade barbs over high drug costs 3:10 p.m. June 2, 2014 - blogs.marketwatch.com
Industry titan UnitedHealth misses boom in sector 10:53 a.m. May 29, 2014 - Russ Britt
Gilead says its drug gives hepatitis C patients more cost-effective cure 5:06 p.m. April 30, 2014 - blogs.marketwatch.com
Why a diverse ETF portfolio is right for these times 6:29 a.m. April 30, 2014 - John Prestbo
Internet, biotech could spawn next Apple: Allianz CIO 7:12 a.m. April 29, 2014 - Barbara Kollmeyer
What Obamacare problems? Aetna results not showing any ill effects 12:34 p.m. April 24, 2014 - blogs.marketwatch.com
U.S. stocks tumble; S&P 500 ends 6-day run 4:46 p.m. April 23, 2014 - Anora Mahmudova
Apple, Facebook stuck in red ahead of earnings 3:02 p.m. April 23, 2014 - Saumya Vaishampayan
U.S. stock futures pause after six-session win streak 8:57 a.m. April 23, 2014 - Sara Sjolin
Game day for Facebook and Apple, volume 'signalling the nasty' 6:50 a.m. April 23, 2014 - blogs.marketwatch.com
Apple, Facebook, Boeing are stocks to watch 5:30 a.m. April 23, 2014 - Sue Chang
Gilead shares climb; AT&T, Amgen shares fall 5:55 p.m. April 22, 2014 - Myra P. Saefong
Gilead scores big on earnings with new drug, but investors getting wary 5:46 p.m. April 22, 2014 - blogs.marketwatch.com
Gilead earnings buoyed by Hepatitis-C drug 5:04 p.m. April 22, 2014 - Anna Prior
Gilead Sciences shares up 4.5% in after-hours trade 4:35 p.m. April 22, 2014 - Myra P. Saefong
Gilead beats expectations; Sovaldi sales hit $2.3 bln 4:22 p.m. April 22, 2014 - Claudia Assis
Gilead: Hep C drug Sovaldi sells $2.27 billion 4:17 p.m. April 22, 2014 - Claudia Assis
Gilead Sciences Q1 non GAAP EPS $1.48 vs. 48c 4:15 p.m. April 22, 2014 - Claudia Assis
Advances In HIV, Hep C Treatments Could Spark Renewed Interest In Biotech Stocks 8:38 a.m. Today - benzinga.com
J&J's Velcade in Focus at the European Hematology Association - Analyst Blog 5:20 p.m. June 17, 2014 - Zacks.com
Vertex Pharmaceuticals Crumbles on Analyst Worries - Analyst Blog 5:00 p.m. June 17, 2014 - Zacks.com
AbbVie's Avenue for Gains 4:47 p.m. June 17, 2014 - Barrons.com
Novartis Submits Bexsero to FDA for Marketing Approval - Analyst Blog 4:47 p.m. June 17, 2014 - Zacks.com
Glaxo's Promacta Holds Promise - Analyst Blog 4:45 p.m. June 17, 2014 - Zacks.com
Ligand Pharma's LGD-6972 Positive in Phase I Study - Analyst Blog 4:35 p.m. June 17, 2014 - Zacks.com
Valeant Receives FDA's Clearance for Restylane - Analyst Blog 3:05 p.m. June 17, 2014 - Zacks.com
Gilead Sciences' (GILD) CEO John Martin Presents at Wells Fargo Healthcare Conference (Transcript) 1:57 p.m. June 17, 2014 - Seeking Alpha
Celgene's Pomalyst Data at European Hematology Association Shows Promise - Analyst Blog 1:40 p.m. June 17, 2014 - Zacks.com
Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves 1:32 p.m. June 17, 2014 - Seeking Alpha
Orexigen (OREX) in Focus: Stock Moves 7.5% Higher - Tale of the Tape 9:46 a.m. June 17, 2014 - Zacks.com
Sequenom Inc. (SQNM) Soars: Stock Rises 9.2% - Tale of the Tape 9:39 a.m. June 17, 2014 - Zacks.com
Achillion Pharmaceuticals (ACHN) Jumps: Stock Up 20.9% - Tale of the Tape 8:51 a.m. June 17, 2014 - Zacks.com
Strength Seen in bluebird bio, Inc. (BLUE) as Stock Shoots up 32.08% - Tale of the Tape 8:44 a.m. June 17, 2014 - Zacks.com
Maxim's $22 Price Target On Achillion Is Far From Realistic 3:33 a.m. June 17, 2014 - Seeking Alpha
Actelion's Selexipag Meets Primary Endpoint - Analyst Blog 6:15 p.m. June 16, 2014 - Zacks.com
Celgene's Vidaza Disappoints in Phase III Study - Analyst Blog 6:10 p.m. June 16, 2014 - Zacks.com
OncoMed's OMP-18R5 On Clinical Hold, Shares Down - Analyst Blog 5:22 p.m. June 16, 2014 - Zacks.com
Agios Presents Data on AG-221 - Analyst Blog 5:21 p.m. June 16, 2014 - Zacks.com
Gilead Sciences to Present at the Wells Fargo Healthcare Conference on Tuesday, June 17 5:00 p.m. June 16, 2014 - BusinessWire - BZX
Gilead Announces Phase 3 Data Showing That the Fixed-Dose Combination of Ledipasvir/Sofosbuvir Achieved 100 Percent Sustained Virologic Response (SVR12) Among Patients with Chronic Hepatitis C in Japan 8:00 p.m. June 15, 2014 - BusinessWire - BZX
Anthera Pharmaceuticals Appoints Dr. Philip Sager to Board of Directors 3:30 p.m. June 13, 2014 - PR Newswire - PRF
Critical Alerts For Ralph Lauren, Rackspace Hosting, Gilead Sciences, Fortinet, and Express Scripts Technology Released By InvestorsObserver 9:31 a.m. June 13, 2014 - PR Newswire - PRF
Prescription for Profit: Pharma-Biotech Industry Continues Mega-Billion Dollar Merger & Acquisition Binge, an Industrial Info News Alert 6:15 a.m. June 11, 2014 - Marketwire
Gilead Sciences to Present at Two Upcoming Investor Conferences on Tuesday, June 10 5:00 p.m. June 9, 2014 - BusinessWire - BZX
Gilead Announces Updated Phase 2 Results for Investigational GS-9973 in Relapsed Chronic Lymphocytic Leukemia 8:30 a.m. June 3, 2014 - BusinessWire - BZX
Stocks Coverage on Biotech Equities -- Research on Gilead Sciences, ARIAD Pharma, Rexahn Pharma, and Geron 7:10 a.m. May 30, 2014 - PR Newswire - PRF
Clinical Study Results, Schedule of Upcoming Conferences, Dividend Declaration, and Services Agreement - Analyst Notes on Gilead, Quest Diagnostics, Sarepta Therapeutics, Incyte and Centene 5:10 a.m. May 28, 2014 - PR Newswire - PRF
AHF: ‘Negligent Corporate Welfare’ Pushes Gilead to Top of S&P 500 5:40 p.m. May 22, 2014 - BusinessWire - BZX
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape 12:38 p.m. May 22, 2014 - PR Newswire - PRF
Gilead’s Investigational GS-5806 Reduces Viral Load and Clinical Symptoms in Phase 2 Respiratory Syncytial Virus (RSV) Challenge Study in Adults 5:00 p.m. May 20, 2014 - BusinessWire - BZX
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology 7:40 a.m. May 20, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 2014 UBS Healthcare Conference on Tuesday, May 20 5:00 p.m. May 19, 2014 - BusinessWire - BZX
Critical Alerts For Goldman Sachs, Noodles & Company, Starbucks, Gilead Sciences, and Time Warner Cable Released By InvestorsObserver 9:31 a.m. May 14, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the Bank of America Merrill Lynch 2014 Health Care Conference on Wednesday, May 14 5:00 p.m. May 13, 2014 - BusinessWire - BZX
Gilead Announces Phase 1 Data for Investigational Therapy, GS-6615, in Patients with Long QT-3 Syndrome 4:31 p.m. May 9, 2014 - BusinessWire - BZX
Cancer Diagnostics Partnering Terms and Agreements 5:41 p.m. May 7, 2014 - PR Newswire - PRF
Gilead Announces $5 Billion Share Repurchase Program 5:17 p.m. May 7, 2014 - BusinessWire - BZX
Medivir: a Supplemental New Drug Application Has Been Submitted to the U.S. FDA for Simeprevir in Combination with Sofosbuvir 8:06 a.m. May 7, 2014 - BusinessWire - BZX
(0)
(0)Scroll down for more posts ▼